Overview
MacroGenics has a diverse portfolio of product candidates with several clinical trials currently underway or planned. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly.
| Program | Target / Modality | Lead Indication(s) | Preclinical | Phase 1 Dose Finding |
Phase 1/2 PoC | Phase 2/3 Pivotal | Partner | ||
|---|---|---|---|---|---|---|---|---|---|
 Antibody Drug Conjugates |
|||||||||
| MGC026 | B7-H3 / TOP1i | Solid Tumors |
|
||||||
| MGC028 | ADAM9 / TOP1i | Solid Tumors |
|
||||||
| MGC030 | Undisclosed / TOP1i | Solid Tumors |
|
||||||
 Dual Checkpoint |
|||||||||
| Lorigerlimab | PD-1 × CTLA-4 / DART® | LINNET Study (PROC/CCGC) |
|
||||||
 T-Cell Engagers |
|||||||||
| MGD024 |
CD123 × CD3 / DART | CD123+ Heme Malignancies |
|
Exclusive Option |
|||||
| Bispecific (Undisclosed) | Undisclosed / TRIDENT® | Solid Tumors |
|
|
|||||
| Bispecific (Undisclosed) | Undisclosed / DART | Undisclosed |
|
|
|||||
Oncology
Solid Tumors
Modality: B7-H3 / TOP1i
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
|
|
|||
MGC028 (ADAM9)
Multiple Solid Tumors
Modality: ADC
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
|
|
|||
Solid Tumors
Undisclosed / TOP1i
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
|
|
|||
LINNET Study (PROC/CCGC)(a)
Modality: PD-1 × CTLA-4 / DART
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
|
|
|||
MGD024 (CD123 × CD3)
CD123+ Heme Malignancies
Modality: CD123 × CD3 / DART
| Preclinical | Phase 1 | Phase 1/2 PoC | Phase 2/3 Pivotal |
|---|---|---|---|
|
|
|||
Partner
Exclusive Option
Bispecific (Undisclosed)
Solid Tumors
Modality: Undisclosed / TRIDENT®
| Preclinical | Phase 1 | Phase 1/2 PoC | Phase 2/3 Pivotal |
|---|---|---|---|
|
|
|||
Partner
Undisclosed / DART
T-Cell Engager
| Preclinical | Phase 1 | Phase 1/2 PoC | Phase 2/3 Pivotal |
|---|---|---|---|
|
|
|||
Partner
ZYNYZ®
(retifanlimab-dlwr)
(retifanlimab-dlwr)
Licensed to Incyte Corporation with a subsequent royalty monetization transaction, ZYNYZ is approved for metastatic or recurrent Merkel cell carcinoma and, in combination or as monotherapy, for certain patients with squamous cell carcinoma of the anal canal.
MARGENZA®
(margetuximab-cmkb)
(margetuximab-cmkb)
Sold to TerSera Therapeutics LLC in a global rights transaction, MARGENZA is approved in combination with chemotherapy for adult patients with metastatic HER2-positive breast cancer after prior anti-HER2 therapies.
TZIELD®
(teplizumab-mzwv)
(teplizumab-mzwv)
Sold via an asset purchase to Provention Bio (now part of Sanofi) with a subsequent royalty sale, TZIELD is approved to delay the onset of Stage 3 type 1 diabetes in at-risk patients with Stage 2 disease.
